Observations placeholder
Sprycel
Identifier
020046
Type of Spiritual Experience
Background
A description of the experience
Dasatinib, previously known as BMS-354825, is a cancer drug sold under the trade name Sprycel. Dasatinib is an oral Bcr-Abl tyrosine kinase inhibitor (inhibits the "Philadelphia chromosome") and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML)[1] and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer.
Adverse effects
Neutropenia and myelosuppression are common toxic effects. Fifteen patients (of 84, i.e. 18%) in one study developed pleural effusions, which were felt to be a side effect of dasatinib. Some of these patients required thoracentesis or pleurodesis to treat the effusions. Other adverse events include diarrhea, peripheral edema, and headache. Patients have developed abnormal liver function. Mild hypocalcemia was also noted. Several cases of pulmonary arterial hypertension (PAH) have been found in patients treated with dasatinib
On October 11, 2011 the U.S. Food and Drug Administration (FDA) announced that dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (pulmonary hypertension, PAH). Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs). In reported cases, patients developed PAH after starting dasatinib, including after more than one year of treatment.
Information about this risk has been added to the Warnings and Precautions section of the Sprycel drug label.
On Jan, 06, 2017 10,399 people reported to have side effects when taking Sprycel.
Among them, 4 people (0.04%) have Hallucination
On Jan, 31, 2016: 4,008 people reported to have side effects when taking Sprycel. Among them, 229 people (5.71%) have Death.
Time on Sprycel when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 29.17% | 50.00% | 8.33% | 12.50% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Sprycel :
| Female | Male | |
| Death | 34.74% | 65.26% |
Age of people who have Death when taking Sprycel :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 1.78% | 2.37% | 13.02% | 20.12% | 15.98% | 46.75% |